I agree with your last paragraph regarding $50 a share valuation.
But what you and some people fail to acknowledge is Reata's drug is approved in US and Europe. But 2591 is still a Phase 2 drug. There is a lot of water to go under the bridge before $22B peak sales can be priced in. As some people pointed out, no one is going to pay the takeover price based on what the peak sales is worth in 6 or 7 years time before the Phase 3 trial has even started. Trial costs, share dilution Neuren deciding to license it out would all have a bearing on what the end value of 2591 will be for Neuren.
- Forums
- ASX - By Stock
- NEU
- Neuren Media and Analyst Coverage
Neuren Media and Analyst Coverage, page-1147
Featured News
Add NEU (ASX) to my watchlist
(20min delay)
|
|||||
Last
$12.20 |
Change
-0.010(0.08%) |
Mkt cap ! $1.559B |
Open | High | Low | Value | Volume |
$12.20 | $12.39 | $12.10 | $2.106M | 172.3K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 750 | $12.11 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$12.35 | 500 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 750 | 12.110 |
1 | 1331 | 12.100 |
1 | 248 | 12.080 |
1 | 500 | 12.070 |
1 | 247 | 12.060 |
Price($) | Vol. | No. |
---|---|---|
12.350 | 500 | 1 |
12.400 | 821 | 1 |
12.500 | 600 | 1 |
12.570 | 310 | 1 |
12.660 | 406 | 1 |
Last trade - 14.10pm 25/12/2024 (20 minute delay) ? |
Featured News
NEU (ASX) Chart |